Edap Tms (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
A number of other equities analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Edap Tms in a research note on Tuesday. ValuEngine upgraded Edap Tms from a “hold” rating to a “buy” rating in a research note on Monday, July 16th. Finally, TheStreet upgraded Edap Tms from a “d+” rating to a “c” rating in a research note on Tuesday, June 26th.
Shares of NASDAQ EDAP traded down $0.09 during trading hours on Friday, reaching $2.80. 53,200 shares of the stock were exchanged, compared to its average volume of 274,376. The firm has a market cap of $85.25 million, a P/E ratio of -280.00 and a beta of 0.52. The company has a current ratio of 2.45, a quick ratio of 2.04 and a debt-to-equity ratio of 0.05. Edap Tms has a 52 week low of $2.07 and a 52 week high of $4.25.
Edap Tms (NASDAQ:EDAP) last announced its earnings results on Wednesday, August 29th. The medical equipment provider reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01). The firm had revenue of $10.14 million for the quarter, compared to the consensus estimate of $10.74 million. Edap Tms had a negative return on equity of 4.04% and a negative net margin of 3.55%. analysts forecast that Edap Tms will post -0.01 EPS for the current year.
An institutional investor recently raised its position in Edap Tms stock. Archon Capital Management LLC lifted its position in shares of Edap Tms SA (NASDAQ:EDAP) by 7.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,019,011 shares of the medical equipment provider’s stock after purchasing an additional 71,336 shares during the period. Edap Tms accounts for approximately 0.2% of Archon Capital Management LLC’s investment portfolio, making the stock its 14th biggest holding. Archon Capital Management LLC owned approximately 3.51% of Edap Tms worth $2,364,000 at the end of the most recent reporting period. Institutional investors own 8.13% of the company’s stock.
Edap Tms Company Profile
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.